Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
#IndianPharma #PharmaSector #ChronicCare #HealthcareTrends #LongTermGrowth #ShareIndia #ShareIndiaResearch To view or add a comment, sign in A new real-world study by analytics firm nference shows that a notable portion of patients may sustain weight loss even after stopping GLP-1 obesity drugs from Novo Nordisk and Eli Lilly, Reuters reported
& Bolten, D
In clinical trials of semaglutide 2.4 mg for weight management (STEP 1), approximately 44% of participants experienced nausea, compared to about 16% in placebo groups
The molecule is different in structure from semaglutide, and the same approach may not work
This suggests that researchers can expect similar outcomes from either compound when using equivalent dosing approaches
doi:10.1016/j.jtemb.2016.12.009 [60] Ventura M, Melo M, Carrilho F
US$ 20.50
US$ 25.77
US$ 21.82
US$ 27.36
